Screening-preventable cervical cancer risks: Evidence from a nationwide audit in Sweden

Journal of the National Cancer Institute

Volumn 100, Issue 9, 2008, Pages 622-629

  Andrae, Bengt ^a   Kemetli, Levent ^b   Sparén, Pär ^c   Silfverdal, Lena ^d   Strander, Björn ^e   Ryd, Walter ^e   Dillner, Joakim ^f   Törnberg, Sven ^b  

^a GÄVLE HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PAPANICOLAOU TEST; POPULATION RESEARCH; PRIORITY JOURNAL; SWEDEN; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; ADENOCARCINOMA; ADULT; CANCER STAGING; CASE CONTROL STUDY; HEALTH CARE QUALITY; INCIDENCE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PRIMARY PREVENTION; REGISTER; RISK; RISK ASSESSMENT; RISK FACTOR; SQUAMOUS CELL CARCINOMA; STANDARD; STATISTICAL MODEL; TREATMENT REFUSAL; UTERINE CERVIX TUMOR; VAGINA SMEAR;

ADENOCARCINOMA; ADULT; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MASS SCREENING; MEDICAL AUDIT; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PRIMARY PREVENTION; PROGRAM EVALUATION; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TREATMENT REFUSAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 44049097019     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn099     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Socialstyrelsen. Cancer Incidence in Sweden 2005. Stockholm, Sweden: National Board of Health and Welfare; 2007.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265.
4. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604-615.
5. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23(17-18):2388- 2394.
6. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191-2199.
7. Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 1999;81(1):159-166.
8. Madlensky L, Goel V, Polzer J, Ashbury FD. Assessing the evidence for organised cancer screening programmes. Eur J Cancer. 2003;39(12):1648- 1653.
9. Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677-686.
10. Andrae B, Smith P. Clinical impact of quality assurance in an organized cervical screening program. Acta Obstet Gynecol Scand. 1999;78(5):429-435.
11. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88(10):2283-2289.
12. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675-683.
13. Sasieni P, Cuzick J. Routine audit is an ethical requirement of screening. BMJ. 2001;322(7295):1179.
14. Slater DN, Milner PC, Radley H. Audit of deaths from cervical cancer: proposal for an essential component of the National Screening Programme. J Clin Pathol. 1994;47(1):27-28.
15. McKenzie CA, Duncan ID. The value of cervical screening in women over 50 years of age-time for a multicentre audit. Scott Med J. 1998;43(1):19-20.
16. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89(1):88-93.
17. Dillner J. Cervical cancer screening in Sweden. Eur J Cancer. 2000;36(17):2255-2259.
18. Socialstyrelsen. Gynekologisk cellprovskontroll. Stockholm, Sweden: National Board of Health and Welfare; 1998.
19. Loos AH, Bray F, McCarron P, Weiderpass E, Hakama M, Parkin DM. Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality. Eur J Cancer. 2004;40(18):2794-2803.
20. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305-313.
21. Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S43-S103.
22. KVAST Swedish Society of Pathology. Exfoliativ cytologi - Vaginalcytologi. http://www3.svls.se/sektioner/pa/Vaginalcytologiv2.pdf. (in Swedish) 2006. Accessed February 3, 2008.
23. Weiss NS. Application of the case-control method in the evaluation of screening. Epidemiol Rev. 1994;16(1):102-108.
24. Weiss NS. Case-control studies of the efficacy of screening tests designed to prevent the incidence of cancer. Am J Epidemiol. 1999;149(1):1-4.
25. Cohen MM. Using administrative data for case-control studies: the case of the Papanicolaou smear. Ann Epidemiol. 1993;3(1):93-98.
26. Sigurdsson K, Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964-2002: a study on trends in incidence and mortality and the effect of risk factors. Acta Obstet Gynecol Scand. 2006;85(3):343-349.
27. Chan PG, Sung HY, Sawaya GF. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. Obstet Gynecol. 2003;102(4):765-773.
28. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer. 1999;83(1):59-65.
29. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer. 2005;113(6):1005-1009.
30. Herbert A, Singh N, Smith JA. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology. 2001;12(1):26-36.
31. Zheng T, Holford TR, Ma Z, et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol. 1996;25(2):252-258.
32. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer. 1998;75(4):536-545.
33. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer. 2003;99(6):336-341.
34. Rieck GC, Tristram A, Hauke A, Fielder H, Fiander AN. Cervical screening in 20-24-year olds. J Med Screen. 2006;13(2):64-71; discussion 62-63.
35. Nygard JF, Nygard M, Skare GB, Thoresen SO. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program. Cancer Causes Control. 2005;16(4):463-474.
36. Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. Acta Cytol. 2003;47(2):167-171.
37. Andersson-Ellstrom A, Seidal T, Grannas M, Hagmar B. The pap-smear history of women with invasive cervical squamous carcinoma. A case-control study from Sweden. Acta Obstet Gynecol Scand. 2000;79(3):221-226.
38. Kenter GG, Schoonderwald EM, Koelma IA, Arentz N, Hermans J, Fleuren GJ. The cytological screening history of 469 patients with squamous cell carcinoma of the cervix uteri; does interval carcinoma exist? Acta Obstet Gynecol Scand. 1996;75(4):400-403.
39. Department of Health Publications. NHSCSP: Guidelines on Failsafe Actions. Publication No. 21, 2004. Sheffield, England.
40. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 1999;318(7188):904-908.
41. Howe A, Owen-Smith V, Richardson J. Health authority cervical screening recall policies and time since last smear: a retrospective cohort analysis in the north west England. J Med Screen. 2003;10(4):184-188.